Brain Health

Find More: Dr. Gabrielle Lyon
- Advertisement -
Ad image

Brain Health Articles

MAPS Submits Cannabis Data Safety Update Report 2024 and Protocol Amendment to FDA on Phase 2 Study of Smoked Cannabis for Veterans with PTSD (MJP2)

On January 15, 2025, MAPS submitted to the FDA the 2024 Cannabis Data Safety Update Report (DSUR) along with a protocol…

The Ultimate Diet Coaching App: Why I Recommend Carbon

Navigating the world of nutrition and fitness apps can feel daunting. With countless options promising results, how do you decide…

MAPS Successfully Clears Path for Cannabis Research through FDA Formal Dispute

FOR IMMEDIATE RELEASE: November 20, 2024 The U.S. Food and Drug Administration (FDA) Division of Psychiatry Products has cleared the…

MAPS cleared to proceed by FDA on Phase 2 Study of Smoked Cannabis for Veterans with PTSD (MJP2)

On November 7, 2024, MAPS received notice from the FDA that the Phase 2 study of Cannabis for Veterans with…

Protected: MAPS cleared to proceed by FDA on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)– Clinical Hold Removed!

There is no excerpt because this is a protected post.

Protected: MAPS submits sixth (and final?!) Clinical Hold Response to FDA on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2) to lift ongoing clinical hold

There is no excerpt because this is a protected post.

Protected: MAPS achieves agreement on three key points despite “Appeal Denied” letter received from FDA on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

There is no excerpt because this is a protected post.

Protected: MAPS Submits Formal Dispute Resolution Request Against FDA’s Clinical Hold on Phase 2 Study of Cannabis for Veterans with PTSD (MJP2)

There is no excerpt because this is a protected post.

Protected: Test MJP2 post

There is no excerpt because this is a protected post.